Calithera Biosciences has commenced a Phase I/II clinical trial of its telaglenastat (CB-839) in combination with Pfizer’s palbociclib (Ibrance) for the treatment of cancer.
Telaglenastat is a glutaminase inhibitor, while palbociclib inhibits cyclin-dependent kinase (CDK) 4/6.
Genetic alterations, including KRAS mutations, are known to lead to increased glutamine metabolism in cancer cells.
Preclinical studies in KRAS-mutated cancer models demonstrated that telaglenastat has synergistic anti-tumour effects when combined with CDK4/6 inhibitors. This synergistic approach was observed to boost cell cycle arrest and block cancer cell proliferation.
The open-label Phase I/II trial will assess the safety and anti-tumour activity of the combination in locally advanced/metastatic KRAS-mutated colorectal cancer (CRC) patients.
The study will also involve participants with KRAS-mutated non-small cell lung cancer (NSCLC). Patients who are refractory or intolerant to standard therapies will be enrolled.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The first subject in the trial has already been treated with a combination of telaglenastat and palbociclib.